Last reviewed · How we verify
NRTIs
NRTIs is a Small molecule drug developed by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. It is currently FDA-approved. Also known as: Nucleoside Reverse Transcriptase Inhibitor, Nucleoside/Nucleotide Reverse Transcription Inhibitors.
At a glance
| Generic name | NRTIs |
|---|---|
| Also known as | Nucleoside Reverse Transcriptase Inhibitor, Nucleoside/Nucleotide Reverse Transcription Inhibitors |
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (PHASE2)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRTIs CI brief — competitive landscape report
- NRTIs updates RSS · CI watch RSS
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections portfolio CI
Frequently asked questions about NRTIs
What is NRTIs?
NRTIs is a Small molecule drug developed by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
Who makes NRTIs?
NRTIs is developed and marketed by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (see full Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections pipeline at /company/advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections).
Is NRTIs also known as anything else?
NRTIs is also known as Nucleoside Reverse Transcriptase Inhibitor, Nucleoside/Nucleotide Reverse Transcription Inhibitors.
What development phase is NRTIs in?
NRTIs is FDA-approved (marketed).
Related
- Manufacturer: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections — full pipeline
- Also known as: Nucleoside Reverse Transcriptase Inhibitor, Nucleoside/Nucleotide Reverse Transcription Inhibitors
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing